Where does Medicenna Therapeutics Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medicenna Therapeutics Inc. ranks #26,829 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medicenna Therapeutics Inc. hold?

Medicenna Therapeutics Inc. holds 10 US utility patents granted between 2018 and 2025, spanning 6 technology areas.

What is Medicenna Therapeutics Inc.'s Innovation Score?

Medicenna Therapeutics Inc. has an Innovation Score of 36.8 out of 100 (top 45% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medicenna Therapeutics Inc. focus on?

Medicenna Therapeutics Inc.'s top technology area is C07K (Peptides) with 10 patents, ranking #887 of 3,615 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Medicenna Therapeutics Inc.'s patent grant rate increasing or decreasing?

Medicenna Therapeutics Inc.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Medicenna Therapeutics Inc.'s patents?

Medicenna Therapeutics Inc.'s patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Medicenna Therapeutics Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medicenna Therapeutics Inc.

USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medicenna ranks #26,829 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 6 technology areas.

#26,829
of 49,997 US assignees by volume: Top 45%
by Innovation Score (36.8/100): 16.4
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26829 · Foreign Corporation #26,829 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,829/49,997
PHOTO-FINISH MedHab
CPC-NARROW C07K · 6 areas
INNOV-THIN 36.8/100
CLAIMS-RICH 16.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: MedHab, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medicenna’s 36.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (23%) Velocity 10.0 pts (27%) Breadth 8.7 pts (24%) Claim depth 9.8 pts (27%)

Qualcomm Incorporated · highest

85
Medicenna Therapeutics · this assignee

37
3D Lighting… · lowest

7

What this shows Medicenna's Innovation Score is 36.8/100 (top 45% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medicenna?

Each dot is one of Medicenna’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medicenna’s own 16.4 claims/patent is ABOVE the 11.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Medicenna vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medicenna's grants concentrate

Medicenna Therapeutics Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2020. By volume, Medicenna sits between MedHab, LLC and Mercury Mission Systems, LLC.

Medicenna's three-year grant acceleration

Medicenna Therapeutics Inc. shows 3 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Medhab

10
Medisynergics

10
Medivena Sp z o o

10
Medicasafe

10
Medimetrics Perso…

10
Medtec

10
Memory Effect Med…

10
Mercury Mission S…

10
Medicenna Therape… ◀

10

What this shows Medicenna holds 10 patents at rank #26,873, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medicenna

By rank, the assignees closest to #26,873 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Medicenna's primary technology class.

Medicenna's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 45% higher than 55% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Medicenna Therapeutics Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	2	20.0%
2020	1	10.0%
2021	1	10.0%
2022	1	10.0%
2023	2	20.0%
2025partial year	3	30.0%

Which technologies does Medicenna Therapeutics Inc. patent most?

C07K - Peptides 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 9

Y02A - Technologies FOR Adaptation TO Climate Change 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medicenna Therapeutics Inc.'s patent record in context - here's where to go next.

Medicenna Therapeutics Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #26,829 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medicenna Therapeutics Inc. against MedHab, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.